Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Mol Cancer Res. 2020 Dec 30;19(4):667–677. doi: 10.1158/1541-7786.MCR-20-0579

Figure 6:

Figure 6:

Combined USP18, ATGL and UCP1 expression profiles independently determined in prostate cancers, kidney chromophobes and low grade gliomas. Comparisons of USP18, ATGL and UCP1 mRNA levels were assessed between: (A) normal prostate and malignant prostate (B) normal kidney versus kidney chromophobe and (C) low grade gliomas. Kaplan-Meier analysis of survival was determined in (D) prostate cancer (E) kidney chromophobe and (F) low grade glioma cases comparing high USP18, ATGL and UCP1 expression profiles versus all other cases.